Preference Tiotropium Respimat Study in COPD
Preference Tiotropium Respimat Study in COPD
In COPD the patient's ability to use inhalers correctly and their preference for the inhaler
 are both important factors in selecting an appropriate treatment for COPD. This is a
 cross-sectional study where satisfaction, preference and handling of two different devices
 such as Respimat and Breezhaler will be evaluated by using the validated PASAPQ in COPD
 patients
Purpose:

 Study Design:
Inclusion criteria:

 1. All patients must sign an informed consent consistent with International Conference on
 Harmonization - Good Clinical Practice (ICH-GCP) guidelines prior to participation in
 the study and conducting any study procedures.

 2. Adult male or female patients with chronic obstructive pulmonary disease (COPD) for
 less than a year who follow usual clinical practice of the participant sites and who
 are on treatment with Spiriva® Respimat®, Hirobriz® Breezhaler® / Onbrez® Breezhaler®
 / Oslif® Breezhaler® for at least of 3 months but not more than maximum of 6 months
 before the informed consent date.

 Exclusion criteria:

 1. Previously included in this study or currently participating in another interventional
 study.

 2. Visual, cognitive, or motor impairment that as judged by the investigator does not
 allow the patient to independently read and complete the questionnaire.

 3. Patients who are treated simultaneously with both respiratory medications (Spiriva®
 Respimat® and Hirobriz® Breezhaler® / Onbrez® Breezhaler® / Oslif® Breezhaler®).